---
title: "Clinuvel Pharmaceuticals  (CLVLF) was downgraded to a Hold Rating at Morgans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297444018.md"
description: "Morgans downgraded Clinuvel Pharmaceuticals (CLVLF) to a Hold rating with an A$10.00 price target, citing analyst Iain Wilkie's assessment. This follows a similar Hold rating from Bell Potter on August 27. Conversely, MA Financial Group maintained its Buy rating on the stock yesterday."
datetime: "2026-08-31T00:35:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297444018.md)
  - [en](https://longbridge.com/en/news/297444018.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297444018.md)
generator: "portal-rs"
---

# Clinuvel Pharmaceuticals  (CLVLF) was downgraded to a Hold Rating at Morgans

Clinuvel Pharmaceuticals received a Hold rating and a A$10.00 price target from Morgans analyst Iain Wilkie today.

According to TipRanks, Wilkie is an analyst with an average return of -11.7% and a 31.78% success rate. Wilkie covers the Healthcare sector, focusing on stocks such as Pro Medicus Limited, Somnomed Limited, and Mach7 Technologies.

In addition to Morgans, Clinuvel Pharmaceuticals also received a Hold from Bell Potter’s Thomas Wakim in a report issued on August 27. However, yesterday, MA Financial Group maintained a Buy rating on Clinuvel Pharmaceuticals (Other OTC: CLVLF).

### Related Stocks

- [CUVL.US](https://longbridge.com/en/quote/CUVL.US.md)
- [CUV.AU](https://longbridge.com/en/quote/CUV.AU.md)
- [PME.AU](https://longbridge.com/en/quote/PME.AU.md)
- [SOM.AU](https://longbridge.com/en/quote/SOM.AU.md)
- [M7T.AU](https://longbridge.com/en/quote/M7T.AU.md)
- [MAF.AU](https://longbridge.com/en/quote/MAF.AU.md)

## Related News & Research

- [Clinuvel Unveils ZEROKIN Single-Use Device for Controlled-Release Drug Delivery](https://longbridge.com/en/news/298443300.md)
- [Clinuvel posts FY2026 net profit after tax of A$34 million, cash reserves rise to A$252 million](https://longbridge.com/en/news/297115070.md)
- [Morgan Stanley Remains a Buy on Telix Pharmaceuticals (TLPPF)](https://longbridge.com/en/news/298377353.md)
- [Macquarie Keeps Their Hold Rating on Region Group (SCPAF)](https://longbridge.com/en/news/298185411.md)
- [Macquarie Reaffirms Their Buy Rating on Megaport (MGPPF)](https://longbridge.com/en/news/298158915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**